Literature DB >> 28654357

Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study.

Luis Ruano1, Mariana Branco2, Emilio Portaccio3, Benedetta Goretti4, Claudia Niccolai4, Francesco Patti5, Clara Chisari5, Paolo Gallo6, Paola Grossi6, Angelo Ghezzi7, Marco Roscio7, Flavia Mattioli8, Chiara Stampatori8, Marta Simone9, Rosa Gemma Viterbo10, Maria Pia Amato4.   

Abstract

BACKGROUND: Patients with paediatric-onset multiple sclerosis (POMS) could be at an increased risk for cognitive impairment (CI), given the potential harmful effects of disease activity in neurodevelopment. However, there is scarce information on their long-term cognitive outcomes.
OBJECTIVE: To compare the prevalence and profile of CI between adults with a history of POMS and those with classic, adult-onset multiple sclerosis (AOMS).
METHODS: Cognitive performance was assessed through the Brief Repeatable Battery (BRB) and the Stroop Test in consecutive patients referred to six Italian MS centres. CI was defined as impairment in ⩾2 cognitive domains.
RESULTS: In all, 119 patients with POMS and 712 with AOMS were included in this analysis. The prevalence of CI was 48.0% in AOMS, 44.5% in POMS; with similar neuropsychological profile between the two groups. However, when adjusting for current age, we found a significantly increased risk for CI (odds ratio (OR) = 1.71; p = 0.02) and for impairment in information processing speed (OR = 1.86; p < 0.01) in patients with POMS. A higher Expanded Disability Status Scale (EDSS) was also identified in POMS ( p = 0.03) compared with AOMS patients.
CONCLUSION: Patients with a history of POMS appear to be at higher risk of physical and cognitive disability than AOMS patients, after correcting for age effects, with particular involvement of information processing speed.

Entities:  

Keywords:  Multiple sclerosis; cognitive impairment; epidemiology; paediatric onset

Mesh:

Year:  2017        PMID: 28654357     DOI: 10.1177/1352458517717341

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.

Authors:  Monica Margoni; Francesca Rinaldi; Alice Riccardi; Silvia Franciotta; Paola Perini; Paolo Gallo
Journal:  J Neurol       Date:  2019-09-27       Impact factor: 4.849

Review 2.  Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.

Authors:  Marisa McGinley; Ian T Rossman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.

Authors:  Gabrielle Macaron; Jenny Feng; Manikum Moodley; Mary Rensel
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.972

4.  Determinants of quality of life in pediatric- and adult-onset multiple sclerosis.

Authors:  Kyla A McKay; Olivia Ernstsson; Ali Manouchehrinia; Tomas Olsson; Jan Hillert
Journal:  Neurology       Date:  2019-11-15       Impact factor: 9.910

Review 5.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

Review 6.  Current Advances in Pediatric Onset Multiple Sclerosis.

Authors:  Kristen S Fisher; Fernando X Cuascut; Victor M Rivera; George J Hutton
Journal:  Biomedicines       Date:  2020-03-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.